Clinical Trial Detail

NCT ID NCT02579863
Title Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

multiple myeloma

Therapies

Pembrolizumab

Dexamethasone

Lenalidomide

Age Groups: adult

No variant requirements are available.